MeSH tree: D12.776.543.750.705.816
The application of CAR immunotherapies to neurodegenerative diseases is limited by major challenges due to the complex nature of these pathologies and the heterogeneity of harmful molecules to be treated. Nonetheless, and ...
Apr 8, 2026
0
3
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch Syndrome (LS) who are more susceptible to ...
Apr 7, 2026
0
3
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from healthy ones. Now, scientists ...
Mar 10, 2026
0
14
The new generation of Alzheimer's disease drugs—the first proven to change the course of the disease—typically extend independent living for patients by 10 months. Called monoclonal antibodies, they reduce the accumulation ...
Mar 5, 2026
0
126
Researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, ...
Feb 20, 2026
0
12
Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity that "remembers" cancer, ...
Jan 2, 2026
0
84
One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack dangerous cells. Yet a full ...
Dec 16, 2025
0
44
UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment—all without ...
Aug 29, 2025
0
38
Ovarian cancer is the leading cause of death among women with gynecological cancers. The current medical playbook—surgery followed by chemotherapy—initially shows promise. Tumors shrink, sometimes disappearing entirely. But ...
Aug 13, 2025
0
86
New designer proteins created using an AI tool can selectively target peptide segments that bind to markers on diseased cancer cells, acting like molecular flags that signal immune cells to attack and destroy the threats.
